Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188447 | 0.80 | DRD2 (0.54) | DRD2DRD3 | |
| SCHEMBL972955 | 0.76 | KCNH2 (0.34) | — | |
| SCHEMBL20038348 | 0.75 | — | — | |
| SCHEMBL25173291 | 0.74 | DRD2 (0.49) | DRD2DRD3 | |
| SCHEMBL2564441 | 0.73 | DRD2 (0.55) | DRD2DRD3 | |
| SCHEMBL30404065 | 0.73 | DRD2 (0.55) | DRD2DRD3 | |
| SCHEMBL29229639 | 0.72 | DRD2 (0.43) | DRD2DRD3 | |
| SCHEMBL8216855 | 0.72 | — | — | |
| SCHEMBL18290968 | 0.72 | DRD2 (0.57) | DRD2DRD3 | |
| SCHEMBL4249668 | 0.72 | DRD2 (0.57) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1855696-B1 | 9A-CARBAMOYL-Y-AMINOPROPYL- AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY | GLAXOSMITHKLINE ZAGREB (HR) | 2010-04-28 | — | — | EP | claimed |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2008-08-21 | — | — | US | claimed |
| EP-1855696-A2 | 9A-CARBAMOYL-Y-AMINOPROPYL- AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-11-21 | — | — | EP | claimed |
| WO-2006085228-A2 | 9A-CARBAMOYL-Y-AMINOPROPYL AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (GB) | 2006-08-17 | — | — | WO | claimed |
| CN-115531387-A | Pyrazole amide compounds useful as IRAK inhibitors | 里格尔药品股份有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-110234637-B | Pyrazole amide compounds useful as IRAK inhibitors | 里格尔药品股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| CN-113750094-A | Pyrazole compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-107438603-B | Pyrazole compounds and methods of making and using the same | 里格尔药品股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| EP-3286181-B1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20190153006-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10208074-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-9982000-B2 | Pyrazole compounds and method for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-3286181-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2016172560-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-1855696-B1 | 9A-CARBAMOYL-Y-AMINOPROPYL- AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY | GLAXOSMITHKLINE ZAGREB (HR) | 2010-04-28 | — | — | EP | disclosed |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | GLAXOSMITHKLINE ISTRAZIVACKI CENTER ZAGREB D.O.O (HR) | 2008-08-21 | — | — | US | disclosed |
| EP-1855696-A2 | 9A-CARBAMOYL-Y-AMINOPROPYL- AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. (HR) | 2007-11-21 | — | — | EP | disclosed |
| WO-2006085228-A2 | 9A-CARBAMOYL-Y-AMINOPROPYL AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL-AZALIDES WITH ANTIMALARIAL ACTIVITY | GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (GB) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | IRAK3, IRAK1, IRAK2 | DRD2 4768/4885DRD3 4659/4885 |
| US-10208074-B2 | Pyrazole compounds and method for making and using the compounds | IRAK3, IRAK1, IRAK2 | DRD2 4741/4885DRD3 4640/4885 |
| US-20190153006-A1 | PYRAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | DRD2 4768/4885DRD3 4659/4885 |
| US-20160311839-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | DRD2 4741/4885DRD3 4640/4885 |
| US-20080200404-A1 | Novel Antimalarial 9A-Carbamoyl-Aminoalkyl and 9A-Thiocarbamoyl-Aminoalkyl Azalides | DCTD, DHODH, DHRS9 | DRD2 325/4885DRD3 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.